SCM
DSGN icon

Sterling Capital Management’s Design Therapeutics DSGN Stock Holding History

Sterling Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56K Sell
108
-683
-86% -$8.52K ﹤0.01% 3048
2026
Q1 		$8.42K Sell
791
-586
-43% -$5.93K ﹤0.01% 2469
2025
Q4 		$12.9K Sell
1,377
-271
-16% -$2.12K ﹤0.01% 2481
2025
Q3 		$12.4K Buy
1,648
+807
+96% +$4.04K ﹤0.01% 2379
2025
Q2 		$2.83K Buy
841
+299
+55% +$1.12K ﹤0.01% 2808
2025
Q1 		$2.09K Sell
542
-463
-46% -$2.21K ﹤0.01% 2579
2024
Q4 		$6.2K Buy
1,005
+903
+885% +$5.23K ﹤0.01% 2360
2024
Q3 		$549 Buy
+102
New +$480 ﹤0.01% 2825

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sterling Capital Management's DSGN Position: Q2 2026 in Review

Sterling Capital Management reduced its Design Therapeutics (DSGN) stake by 86% in Q2 2026, selling an estimated $8.52K and leaving 108 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

Sterling Capital Management first reported a position in DSGN in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.9K in Q4 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Sterling Capital Management held 108 shares of Design Therapeutics worth $1.56K as of Q2 2026.
  • Sterling Capital Management sold 683 Design Therapeutics shares in Q2 2026, an estimated $8.52K.
  • Design Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3048 holding.
  • Sterling Capital Management first reported a position in Design Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Design Therapeutics position peaked at $12.9K in Q4 2025.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.